

Supplemental Data Table S1. Detailed clinical and laboratory features of 36 patients with CMML

No. Case	Age	Sex	ASXL1 mutation	Karyotype	2008 WHO subtypes	2016 WHO subtypes	FAB subtype	Spanish cytogenetic risk stratification	MDAPS	GFM model	Mayo prognostic model	Mayo molecular model	Outcome
1	73	M	c.1934dupG (p.Gly646Trpfs*12)	46,XY[20]	CMML-1	CMML-0	Proliferative type	Low	Intermediate-1	High	Intermediate	Intermediate-2	Dead
2	71	F	c.1934dupG (p.Gly646Trpfs*12)	46,XX[4]	CMML-1	CMML-1	Proliferative type	Low	Intermediate-1	High	High	High	Dead
3	66	M	c.1934dupG (p.Gly646Trpfs*12)	46,XY[2]	CMML-1	CMML-1	Proliferative type	Low	Intermediate-2	High	High	High	Dead
4	55	F	c.2973_2985del (p.Leu992Valfs*28)	46,XX[20]	CMML-1	CMML-1	Proliferative type	Low	Intermediate-2	Intermediate	Intermediate	Intermediate-2	Dead
5	50	F	-	46,XX,del(9)(q13q22)[2]/46,XX[3]	CMML-2	CMML-2	Dysplastic type	High	Intermediate-1	Low	High	Intermediate-2	Dead
6	83	M	-	46,X,der(Y)(Y:1)(q12;q21)[20]	CMML-1	CMML-0	Proliferative type	Intermediate	Low	Intermediate	Intermediate	Intermediate-1	Dead
7	58	M	c.1934dupG (p.Gly646Trpfs*12)	46,XY,del(7)(q22)[9]	CMML-1	CMML-1	Proliferative type	High	Intermediate-2	Intermediate	High	High	Dead
8	73	M	-	46,XY[20]	CMML-1	CMML-0	Dysplastic type	Low	Intermediate-1	Intermediate	High	High	Dead
9	53	M	-	47,XY,+8[2]/46,XY[28]	CMML-1	CMML-0	Proliferative type	High	Intermediate-2	Intermediate	High	High	Dead
10	38	F	c.1934dupG (p.Gly646Trpfs*12)	46,XX[20]	CMML-1	CMML-1	Dysplastic type	Low	Low	Low	Intermediate	Intermediate-2	Dead
11	71	M	-	45,X,-Y[50]	CMML-1	CMML-0	Dysplastic type	Low	Low	Intermediate	High	Intermediate-2	Dead
12	74	M	-	46,XY[20]	CMML-1	CMML-1	Proliferative type	Low	Intermediate-1	Intermediate	High	Intermediate-2	Dead
13	72	M	-	46,XY[20]	CMML-1	CMML-0	Dysplastic type	Low	Intermediate-1	Low	Intermediate	Intermediate-1	Alive
14	74	M	c.1934dupG (p.Gly646Trpfs*12)	46,XY[20]	CMML-1	CMML-1	Proliferative type	Low	Intermediate-2	Intermediate	High	High	Dead
15	58	M	-	46,XY[20]	CMML-1	CMML-0	Proliferative type	Low	Intermediate-1	Low	High	High	Dead
16	78	M	-	46,XY[20]	CMML-1	CMML-0	Proliferative type	Low	Intermediate-1	Intermediate	High	Intermediate-2	Alive
17	68	M	c.3001dupA (p.Thr1001Asnfs*4)	46,XY[20]	CMML-1	CMML-0	Proliferative type	Low	Low	Intermediate	Intermediate	Intermediate-2	Dead
18	56	F	-	46,XX[20]	CMML-1	CMML-0	Proliferative type	Low	Low	Intermediate	Intermediate	Intermediate-1	Alive
19	70	M	-	46,XY[20]	CMML-1	CMML-1	Dysplastic type	Low	Intermediate-2	Intermediate	High	Intermediate-2	Alive
20	55	M	c.1900_1922del (p.Glu635Argfs*15)	47,XY,+21[19]/46,XY[1]	CMML-1	CMML-1	Proliferative type	High	Intermediate-2	Intermediate	High	High	Dead
21	59	F	-	46,XX[20]	CMML-2	CMML-2	Proliferative type	Low	High	Intermediate	High	Intermediate-2	Alive

(Continued to the next page)

Supplemental Data Table S1. Continued

No. Case	Age	Sex	ASXL1 mutation	Karyotype	2008 WHO subtypes	2016 WHO subtypes	FAB subtype	Spanish cytogenetic risk stratification	MDAPS	GFM model	Mayo prognostic model	Mayo molecular model	Outcome
22	83	M	-	45,X,-Y[12]	CMML-2	CMML-2	Dysplastic type	Low	Low	Low	High	Intermediate-2	Alive
23	72	M	c.1773C>G (p.Tyr591*)	46,XY[20]	CMML-2	CMML-2	Proliferative type	Low	High	High	High	High	Dead
24	60	F	-	46,XX[20]	CMML-2	CMML-2	Proliferative type	Low	High	Intermediate	High	High	Dead
25	76	M	c.1934dupG (p.Gly646Trpfs*12)	45,XY,-7[10]/46,XY[10]	CMML-2	CMML-2	Proliferative type	High	High	High	High	High	Dead
26	75	F	c.1934dupG (p.Gly646Trpfs*12)	46,XX[20]	CMML-2	CMML-2	Proliferative type	Low	High	High	High	High	Dead
27	72	F	-	46,XX[20]	CMML-2	CMML-2	Proliferative type	Low	Intermediate-2	Intermediate	High	Intermediate-2	Alive
28	75	M	c.1766_1767insAGTA (p.Thr590Valfs*30)	46,XY[20]	CMML-2	CMML-2	Dysplastic type	Low	Low	Intermediate	Intermediate	Intermediate-2	Alive
29	79	M	c.1934dupG (p.Gly646Trpfs*12)	46,XY[20]	CMML-2	CMML-2	Proliferative type	Low	Intermediate-2	High	High	High	Dead
30	59	M	c.1934dupG (p.Gly646Trpfs*12)	46,XY[20]	CMML-2	CMML-2	Proliferative type	Low	High	High	High	High	Alive
31	75	M	-	45,XY,del(3)(p21),der(5;6)(p10;p10),add(15)(p11.2)[20]	CMML-2	CMML-2	Dysplastic type	High	High	Intermediate	High	High	Dead
32	70	M	c.2254dupG (p.Ala752Glyfs*22)	46,XY[20]	CMML-2	CMML-2	Dysplastic type	Low	Low	Intermediate	Intermediate	Intermediate-2	Alive
33	75	M	c.1934dupG (p.Gly646Trpfs*12)	46,XY[18]	CMML-2	CMML-2	Proliferative type	Low	Intermediate-2	High	High	High	Dead
34	65	M	c.1934dupG (p.Gly646Trpfs*12)	47,XY,+8[20]	CMML-1	CMML-0	Proliferative type	High	Intermediate-2	Intermediate	High	High	Dead
35	74	M	-	46,XY[20]	CMML-1	CMML-0	Proliferative type	Low	Intermediate-1	Intermediate	High	High	Dead
36	72	F	-	46,XX[10]	CMML-2	CMML-2	Proliferative type	Low	High	High	High	High	Dead

Abbreviations: FAB, French-American-British; MDAPS, MD Anderson prognostic scoring system; GFM, Groupe Français des Myélodysplasies; M, male; F, female; CMML, chronic myelomonocytic leukemia.